US OptionsDetailed Quotes
ORA250516P95000
- 0.00
- 0.000.00%
15min DelayClose Apr 29 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest95.00Strike Price0.00Turnover59.34%IV-29.15%PremiumMay 16, 2025Expiry Date21.44Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9869Delta0.0089Gamma3.43Leverage Ratio-0.0054Theta-0.0087Rho-3.38Eff Leverage0.0048Vega
Ormat Technologies Stock Discussion
Sign in to post a comment
President Donald Trump’s pro-oil policies have significantly impacted various sectors within the energy industry. Companies involved in oil and gas exploration, production, and services have notably benefited from these policy shifts.
Oil and Gas Exploration and Production Companies:
• $Exxon Mobil (XOM.US)$: As a major player in the oil industry, Exxon Mobil stands to gain from policies that encourage increased fossil fuel production and reduced regulatory const...
Oil and Gas Exploration and Production Companies:
• $Exxon Mobil (XOM.US)$: As a major player in the oil industry, Exxon Mobil stands to gain from policies that encourage increased fossil fuel production and reduced regulatory const...
10
1
1
CEO Doron Blachar is optimistic about the new assets enhancing Ormat's profits and is eager to increase shareholder value. The deal underscores Ormat's leadership in renewable energy and its commitment to global renewable power solutions.
2
Insiders at Ormat Technologies' mass stock selling over the past year may suggest a lack of confidence in future performance. Low insider ownership and a continued lack of insider buying is concerning.
Ormat's share price increased despite decreased revenues, suggesting an anomaly that requires further investigation. It's worth considering for investment if long-term growth trend continues.
Loop Capital Downgrades $Apple (AAPL.US)$to Hold From Buy, Price Target at $180
Apple has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $116 to $210.
Citigroup Upgrades $Norfolk Southern (NSC.US)$to Buy From Neutral, Adjusts Price Target to $257 From $226
Norfolk Southern has an average rating of outperform and price targets ranging from $174 to $288, according to analysts ...
Apple has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $116 to $210.
Citigroup Upgrades $Norfolk Southern (NSC.US)$to Buy From Neutral, Adjusts Price Target to $257 From $226
Norfolk Southern has an average rating of outperform and price targets ranging from $174 to $288, according to analysts ...
17
2
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Bath & Body Works (BBWI.US)$ - up 7.8%
2. $Lloyds Banking (LYG.US)$ - up 0.48%
3. $Cisco (CSCO.US)$ - up 0.4%
Gap Downs
1. $Ormat Technologies (ORA.US)$ - down 5.45%
2. $Cloudflare (NET.US)$ - down 3.46%
3. $Spotify Technology (SPOT.US)$ - down 2.62%
4. $Gitlab (GTLB.US)$ - dow...
Gap Ups
1. $Bath & Body Works (BBWI.US)$ - up 7.8%
2. $Lloyds Banking (LYG.US)$ - up 0.48%
3. $Cisco (CSCO.US)$ - up 0.4%
Gap Downs
1. $Ormat Technologies (ORA.US)$ - down 5.45%
2. $Cloudflare (NET.US)$ - down 3.46%
3. $Spotify Technology (SPOT.US)$ - down 2.62%
4. $Gitlab (GTLB.US)$ - dow...
+15
13
1
Gainers:
• $La-Z-Boy (LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals (ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer (PFE.US)$)
• $Ikena Oncology (IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma (BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech (KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
• $La-Z-Boy (LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals (ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer (PFE.US)$)
• $Ikena Oncology (IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma (BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech (KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
8
1
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
jusgod : Yet the several Oil/energy stocks trading very low.......